Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1648BQL

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 3	MAR 16	CASREACT coverage extended
NEWS 4	MAR 20	MARPAT now updated daily
NEWS 5	MAR 22	LWPI reloaded
NEWS 6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS 7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS 8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS 9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS 10	APR 30	CA/CAplus enhanced with 1870-1889 U.S. patent records
NEWS 11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS 12	MAY 01	New CAS web site launched
NEWS 13	MAY 08	CA/CAplus Indian patent publication number format defined
NEWS 14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS 16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS 17	MAY 21	CA/CAplus enhanced with additional kind codes for German patents
NEWS 18	MAY 22	CA/CAplus enhanced with IPC reclassification in Japanese patents
NEWS 19	JUN 27	CA/CAplus enhanced with pre-1967 CAS Registry Numbers
NEWS 20	JUN 29	STN Viewer now available
NEWS 21	JUN 29	STN Express, Version 8.2, now available
NEWS 22	JUL 02	LEMBASE coverage updated
NEWS 23	JUL 02	LMEDLINE coverage updated
NEWS 24	JUL 02	SCISEARCH enhanced with complete author names
NEWS 25	JUL 02	CHEMCATS accession numbers revised
NEWS 26	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 27	JUL 16	CAplus enhanced with French and German abstracts
NEWS 28	JUL 18	CA/CAplus patent coverage enhanced

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

```
* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:24:11 ON 23 JUL 2007

=> file caplus biosis
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.42       0.42

FILE 'CAPLUS' ENTERED AT 15:25:10 ON 23 JUL 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:25:10 ON 23 JUL 2007
Copyright (c) 2007 The Thomson Corporation

=> "chimeric ebola glycoprotein"
L1            0 "CHIMERIC EBOLA GLYCOPROTEIN"

=> Ebola (s) glycoprotein
L2          332 EBOLA (S) GLYCOPROTEIN

=> chimeric
L3        82149 CHIMERIC

=> L3 and L2
L4           20 L3 AND L2

=> truncat3
 75% OF LIMIT FOR TOTAL ANSWERS REACHED
L5     10151636 3

=> L5 and L2
L6           61 L5 AND L2

=> binding (l) domain
L7       205179 BINDING (L) DOMAIN

=> L7 and L6
L8            1 L7 AND L6

=> signal (s) peptide
L9        38064 SIGNAL (S) PEPTIDE

=> L9 and L2
L10           7 L9 AND L2

=> D L8 IBIB ABS

L8   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2001:816888  CAPLUS
DOCUMENT NUMBER:          135:353763
TITLE:                    Recombinant lentiviral vectors pseudotyped in
                          envelopes containing filovirus binding
                          domains for gene delivery in vitro and in vivo
INVENTOR(S):              Kobinger, Gary; Wilson, James M.
PATENT ASSIGNEE(S):       The Trustees of the University of Pennsylvania, USA
SOURCE:                   PCT Int. Appl., 50 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
```

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083730	A2	20011108	WO 2001-US12880	20010420
WO 2001083730	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2004033604	A1	20040219	US 2002-257960	20021025
PRIORITY APPLN. INFO.:			US 2000-200599P P	20000428
			WO 2001-US12880 W	20010420

AB The present invention provides a recombinant transfer virus, in which a lentiviral, in particular HIV, minigene is packaged in a heterologous envelope comprising the binding domain of a filovirus envelope protein. In one particularly desirable embodiment, the filovirus is ebola. Advantageously, the recombinant transfer virus of the invention minimizes the safety concerns that the HIV will form replication competent virus. The lentivirus minigene contains the lentivirus 5' long terminal repeat (LTR) sequences, a mol. for delivery to a host cell, and a functional portion of the lentivirus 3' LTR sequences. In one embodiment, the minigene further contains functional lentiviral RRE (rev-responsive element). These transfer viruses are particularly useful for delivery of mols., in vivo, to mammalian lung cells, as the transfer virus infects from the apical side, permitting delivery via intracheal administration, or for delivery of mols., ex vivo, to macrophages and dendritic cells. Also described are methods of producing these transfer viruses in vitro, or using a packaging cell, and methods of using these viruses to deliver genes to selected target cells. In a tracheal explant model of cystic fibrosis (CF), CF explanted airway could be efficiently transduced using the EboZ pseudotyped virus of the invention despite the presence of some mucus. Thus, the transfer viruses of the invention are particularly well suited for delivery of mols. to airway cells, e.g., for treatment of CF.

=> D L10 IBIB ABS 1-7

L10 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:672980 CAPLUS
TITLE: Peptides interacting with α-helical coiled-coil structures for treatment of HIV, influenza virus, and Mycobacterium tuberculosis infections
INVENTOR(S): Mahrenholz, Carsten; Portwich, Michael
PATENT ASSIGNEE(S): Charite-Universitaetsmedizin Berlin, Germany
SOURCE: PCT Int. Appl., 74pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007068240	A2	20070621	WO 2006-DE2295	20061218
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,				

KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

DE 102005060920 A1 20070621 DE 2005-102005060920 20051218
PRIORITY APPLN. INFO.: DE 2005-102005060920A 20051218

AB The invention relates to novel peptides which bind to α-helical coiled-coil structures and their use for detecting, marking, and influencing coiled-coil structures in a biol. system, particularly peptides of general formula (abcdefg)n (a-g = amino acids; a and/or d = hydrophobic amino acid; e and/or g = charged amino acid; n = 1-3) which composed of a min. of 2 and a maximum of 15 amino acid residues. The invention further relates to pharmaceutical compns. containing the novel peptides for use in treating HIV, influenza virus, or Mycobacterium tuberculosis infections.

L10 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:711095 CAPLUS
DOCUMENT NUMBER: 145:183885
TITLE: The signal peptide of the Ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR
AUTHOR(S): Marzi, Andrea; Akhavan, Armin; Simmons, Graham; Gramberg, Thomas; Hofmann, Heike; Bates, Paul; Lingappa, Vishwanath R.; Poehlmann, Stefan
CORPORATE SOURCE: Institute for Clinical and Molecular Virology, University Erlangen-Nuernberg, Erlangen, 91054, Germany
SOURCE: Journal of Virology (2006), 80(13), 6305-6317
CODEN: JOVIAM; ISSN: 0022-538X
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The C-type lectins DC-SIGN and DC-SIGNR (collectively referred to as DC-SIGN/R) bind to the ebolavirus glycoprotein (EBOV-GP) and augment viral infectivity. DC-SIGN/R strongly enhance infection driven by the GP of EBOV subspecies. Zaire (ZEBOV) but have a much less pronounced effect on infection mediated by the GP of EBOV subspecies. Sudan (SEBOV). For this study, we analyzed the determinants of the differential DC-SIGN/R interactions with ZEBOV- and SEBOV-GP. The efficiency of DC-SIGN engagement by ZEBOV-GP was dependent on the rate of GP incorporation into lentiviral particles, while appreciable virion incorporation of SEBOV-GP did not allow robust DC-SIGN/R usage. Forced incorporation of high-mannose carbohydrates into SEBOV-GP augmented the engagement of DC-SIGN/R to the levels observed with ZEBOV-GP, indicating that appropriate glycosylation of SEBOV-GP is sufficient for efficient DC-SIGN/R usage. However, neither signals for N-linked glycosylation unique to SEBOV- or ZEBOV-GP nor the highly variable and heavily glycosylated mucin-like domain modulated the interaction with DC-SIGN/R. In contrast, anal. of chimeric GPs identified the signal peptide as a determinant of DC-SIGN/R engagement. Thus, ZEBOV- but not SEBOV-GP was shown to harbor high-mannose carbohydrates, and GP modification with these glycans was controlled by the signal peptide. These results suggest that the signal peptide governs EBOV-GP interactions with DC-SIGN/R by modulating the incorporation of high-mannose carbohydrates into EBOV-GP. In summary, we identified the level of GP incorporation into virions and signal peptide-controlled glycosylation of GP as determinants of attachment factor engagement.

REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:892534 CAPLUS
DOCUMENT NUMBER: 139:386332
TITLE: Chimeric ebola virus envelopes and uses for delivering molecules to target cells
INVENTOR(S): Wilson, James M.; Medina, Maria Fe C.; Kobinger, Gary
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092582	A2	20031113	WO 2003-US11494	20030428
WO 2003092582	A3	20040701		
WO 2003092582	B1	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003232004	A1	20031117	AU 2003-232004	20030428
US 2005255123	A1	20051117	US 2005-510947	20050111
PRIORITY APPLN. INFO.:			US 2002-376480P P	20020430
			US 2002-385704P P	20020604
			US 2002-427752P P	20021120
			WO 2003-US11494 W	20030428

AB The present invention relates to chimeric ebola envelope proteins and uses for delivering mols. to target cells. The chimeric envelope proteins are useful for packaging viral vectors and targeting these vectors in vivo, to lung cells following intratracheal delivery or for delivery of mols., ex vivo, to macrophages and dendritic cells. In another aspect, also provided herein are immunogenic compns. which contain ebola envelope proteins and uses thereof.

L10 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:634334 CAPLUS
DOCUMENT NUMBER: 137:180775
TITLE: Influenza viruses with enhanced transcription and replication capacities comprising RNA polymerase similar to that of fowl plague virus and uses for gene therapy and vaccination
INVENTOR(S): Hobom, Gerd; Menke, Anette
PATENT ASSIGNEE(S): Artemis Pharmaceuticals Gmbh, Germany
SOURCE: Eur. Pat. Appl., 137 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

EP 1233059 A1 20020821 EP 2001-103060 20010209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
WO 2002064757 A2 20020822 WO 2002-EP1257 20020207
WO 2002064757 A3 20021205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002247689 A1 20020828 AU 2002-247689 20020207
EP 1368459 A2 20031210 EP 2002-716735 20020207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004531232 T 20041014 JP 2002-565072 20020207
US 2003099670 A1 20030529 US 2002-73377 20020208
PRIORITY APPLN. INFO.: EP 2001-103060 A 20010209
US 2001-270135P P 20010220
WO 2002-EP1257 W 20020207

AB The present invention provides human influenza viruses comprising an RNA sequence encoding a modified RNA-polymerase (RNAP). It was found that specific modifications of the RNA sequence encoding the RNAP, in particular the RNAP PB1 subunit - so as to code for a polypeptide having a higher similarity with fowl plague virus strain Bratislava (FPV) RNAP - provides viruses capable of recognition of viral RNA (vRNA) promoter sequence variations (the so called promoter-up variants) leading to an increase in transcription and/or replication initiation rates. The vRNA promoter may comprise the modifications G3A and C8U, or G3C and C8G, preferably G3A, U5C and C8U, or G3C, U5C and C8G in the 3'-terminal region (5'-CCUGUUUCUACU-3' or 5'-CCUGUUUUUACU-3'); and the modifications U3A and A8U in the 5'-terminal region (5'-AGAAGAAUCAAGG-3'). The present invention also provides a process for the preparation thereof, pharmaceutical compns. comprising said human influenza viruses and their use for gene transfer into mammalian cells, for ex vivo gene transfer into antigen-presenting cells, such as dendritic cells, for in vivo somatic gene therapy, or in vivo vaccination purposes. The invention also relates to other non-avian influenza viruses, including equine, porcine influenza viruses.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:326404 CAPLUS
DOCUMENT NUMBER: 131:210688
TITLE: Are the Fusion Processes Involved in Birth, Life and Death of the Cell Depending on Tilted Insertion of Peptides into Membranes?
AUTHOR(S): Peuvot, Jacques; Schanck, Andre; Lins, Laurence; Brasseur, Robert
CORPORATE SOURCE: Medical Affairs, UCB-Pharma, Brussels, Belg.
SOURCE: Journal of Theoretical Biology (1999), 198(2), 173-181
CODEN: JTBIAP; ISSN: 0022-5193
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Various peptide segments have been modeled as asym. amphipathic α-helixes. Theor. calcns. have shown that they insert obliquely into model membranes. They have been named "tilted peptides''. Mol. modeling results reported here also evidence the presence of tilted peptides in ADM-1 protein of Caenorhabditis elegans that may be involved

in fusion events, in meltrin α, a protein implicated in myoblast fusion, in hemagglutinin of influenza virus, in the E2 glycoprotein of rubella virus, in the S protein of hepatitis B virus, in a subdomain of Ebola virus and in the malaria CS protein. Exptl. results have indicated that tilted peptide fragments may be involved in cellular life events like sperm-egg fecundation, muscle development, protein translocation through signal sequences and cellular death caused by viral infection or parasite infestation. We speculate that membrane destabilization by these tilted peptides may be an important common step in life processes involving fusion phenomena. (c) 1999 Academic Press.

REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:1939 CAPLUS
DOCUMENT NUMBER: 120:1939
TITLE: Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus
AUTHOR(S): Sanchez, Anthony; Kiley, Michael P.; Holloway, Brian P.; Auperin, David D.
CORPORATE SOURCE: Div. viral, Natl. Cent. Infect. Dis., Atlanta, GA, 30333, USA
SOURCE: Virus Research (1993), 29(3), 215-40
CODEN: VIREDF; ISSN: 0168-1702
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Sequence anal. of the 2nd through the 6th genes of the Ebola virus (EBO) genome indicates that it is organized similarly to rhabdoviruses and paramyxoviruses and is virtually the same as Marburg virus (MBG). In vitro translation expts. and predicted amino acid sequence comparisons showed that the order of the EBO genes is 3'-NP-VP35-VP40-GP-VP30-VP24-L. The transcriptional start and stop (polyadenylation) signals are conserved and all contain the sequence 3'-UAAUU. Three base intergenic sequences are present between the NP and VP35 genes (3'-GAU) and VP40 and GP genes (3'-AGC), and a large intergenic sequence of 142 bases separates the VP30 and VP24 genes. Novel gene overlaps were found between the VP35 and VP40, the GP and VP30, and the VP24 and L genes. Overlaps are 20 or 18 bases in length and are limited to the conserved sequences determined for the transcriptional signals. Stem-and-loop structures were identified in the putative (+) leader RNA and at the 5' end of each mRNA. Hybridization studies showed that a small 2nd mRNA is transcribed from the glycoprotein gene, and is produced by termination of transcription at an atypical polyadenylation signal located in the middle of the coding region. The predicted amino acid sequence of the glycoprotein contains an N-terminal signal peptide sequence, a hydrophobic anchor sequence, and 17 potential N-linked glycosylation sites. Alignment of predicted amino acid sequences showed that the structural proteins of EBO and MBG contain large regions of homol. despite the absence of serol. cross-reactivity.

L10 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN
ACCESSION NUMBER: 1999:311757 BIOSIS
DOCUMENT NUMBER: PREV199900311757
TITLE: Are the fusion processes involved in birth, life and death of the cell depending on tilted insertion of peptides into membranes?.
AUTHOR(S): Peuvot, Jacques [Reprint author]; Schanck, Andre; Lins, Laurence; Brasseur, Robert
CORPORATE SOURCE: Medical Affairs, UCB-Pharma, allee de la Recherche, 1070, Bruxelles, Belgium
SOURCE: Journal of Theoretical Biology, (May 21, 1999) Vol. 198, No. 2, pp. 173-181. print.

CODEN: JTBIAP. ISSN: 0022-5193.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 17 Aug 1999
Last Updated on STN: 17 Aug 1999

AB Various peptide segments have been modeled as asymmetric amphipathic alpha-helices. Theoretical calculations have shown that they insert obliquely into model membranes. They have been named "tilted peptides". Molecular modeling results reported here also evidence the presence of tilted peptides in ADM-1 protein of Caenorhabditis elegans that may be involved in fusion events, in meltrin alpha, a protein implicated in myoblast fusion, in hemagglutinin of influenza virus, in the E2 glycoprotein of rubella virus, in the S protein of hepatitis B virus, in a subdomain of Ebola virus and in the malaria CS protein. Experimental results have indicated that tilted peptide fragments may be involved in cellular life events like sperm-egg fecondation, muscle development, protein translocation through signal sequences and cellular death caused by viral infection or parasite infestation. We speculate that membrane destabilization by these tilted peptides may be an important common step in life processesinvolving fusion phenomena.

=> deletion and L4
L11 4 DELETION AND L4

=> D L11 IBIB ABS 1-4

L11 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:13711 CAPLUS
DOCUMENT NUMBER: 144:106605
TITLE: Hybrid peptides comprising Ii-Key peptide and antigenic epitope as vaccines against infection, allergy and cancer
INVENTOR(S): Humphreys, Robert; Xu, Minzhen
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 142 pp., Cont.-in-part of U.S. Ser. No. 245,871.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006002947	A1	20060105	US 2005-33039	20050111
US 6432409	B1	20020813	US 1999-396813	19990914
US 2003091582	A1	20030515	US 2002-197000	20020717
US 7205274	B2	20070417		
US 2003235594	A1	20031225	US 2002-245871	20020917
WO 2006076410	A2	20060720	WO 2006-US944	20060111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 1999-396813 A3 19990914
US 2002-197000 A2 20020717
US 2002-245871 A2 20020917
US 2005-33039 A 20050111

AB Disclosed is an antigen presentation enhancing hybrid polypeptide which includes three elements. The first element is an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide LRMKLPKPPKPVSKMR and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity. The second element is a chemical structure covalently linking the N-terminal element described above to the MHC Class II-presented epitope described below. The chemical structure is a covalently joined group of atoms which when arranged in a linear fashion forms a flexible chain which extends up to the length of 20 amino acids likewise arranged in a linear fashion, the chemical structure being selected from the group consisting of: (i) immunol. neutral chemical structures, (ii) a MHC Class I epitope or a portion thereof, and/or (iii) an antibody-recognized determinant or a portion thereof. Finally, the enhancing antigen presentation enhancing hybrid polypeptide includes a C-terminal element comprising an antigenic epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II mol. Methods for the design and testing of these peptides are presented. Provided are protein and nucleic acid sequences for antigens and peptides of the invention. Exemplified proteins are allergen: Ara h 1-3, Fel d 1, Phi p 1, Phl p 5a, Bla q 5, and bee venom phospholipase A2; tumor antigens: CEA, CA-125, PSA, gp100, Pmel17, TRP-2, melanoma tyrosinase, MART-1, and Her-2 neu; pathogenic antigens: anthrax toxin lethal factor, anthrax protective antigen, Variola virus B5R protein, Ebola virus membrane-associated protein VP24, SARS proteins, influenza virus proteins; and autoantigens: myelin basic protein, proteolipid protein, and myelin-oligodendrocyte glycoprotein precursor. Demonstrated are diagnosis and treatment of the early autoimmune phase leading to type I diabetes mellitus.

L11 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:252189 CAPLUS
DOCUMENT NUMBER: 140:286142
TITLE: Hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer
INVENTOR(S): Humphreys, Robert E.; Xu, Minzhen
PATENT ASSIGNEE(S): Antigen Express, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 90 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004058881	A1	20040325	US 2002-253286	20020924
US 7179645	B2	20070220		
CA 2499123	A1	20040415	CA 2003-2499123	20030912
WO 2004030616	A2	20040415	WO 2003-US28574	20030912
WO 2004030616	A3	20041007		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003294220	A1	20040423	AU 2003-294220	20030912
EP 1556072	A2	20050727	EP 2003-789700	20030912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515744	T	20060608	JP 2004-541534	20030912
PRIORITY APPLN. INFO.:			US 2002-245871 A	20020917
			US 2002-253286 A	20020924
			WO 2003-US28574 W	20030912

AB Disclosed is a nucleic acid mol. comprising a first expressible sequence encoding a protein of interest or polypeptide of interest which contains an MHC Class II-presented epitope. In addition, the nucleic acid mol. comprises a second expressible nucleic acid sequence encoding an antigen presentation-enhancing hybrid polypeptide. The antigen presentation enhancing hybrid polypeptide includes the following elements: (i) an N-terminal element consisting essentially of 4-16 residues of the mammalian Ii-Key peptide: LRMKLPKPPKPVSKMR and non-N-terminal deletion modifications thereof that retain antigen presentation enhancing activity; (ii) a C-terminal element comprising an MHC Class II-presented epitope in the form of a polypeptide or peptidomimetic structure which binds to the antigenic peptide binding site of an MHC class II mol., the MHC Class II-presented epitope being contained in the protein of interest of step (a); and (iii) an intervening peptidyl structure linking the N-terminal and C-terminal elements of the hybrid, the peptidyl structure having a length of about 20 amino acids or less. Exemplified proteins are allergen: Ara h 1-3, Fel d 1, Phi p 1, Phl p 5a, Bla q 5, and bee venom phospholipase A2; tumor antigen: CEA, CA-125, PSA, gp100, Pmel17, TRP-2, melanoma tyrosinase, MART-1, and Her-2 neu; pathogenic antigen: anthrax toxin lethal factor, anthrax protective antigen, Variola virus B5R protein, and Ebola virus membrane-associated protein VP24; and autoantigen: myelin basic protein, proteolipid protein, and myelin-oligodendrocyte glycoprotein precursor.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2003:282705 CAPLUS
DOCUMENT NUMBER:	138:282319
TITLE:	Construction of recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses as vaccine
INVENTOR(S):	Wertz, Gail W.; Megaw, George; Oomens, Tom A.
PATENT ASSIGNEE(S):	UAB Research Foundation, USA
SOURCE:	PCT Int. Appl., 80 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029416	A2	20030410	WO 2002-US31086	20021001
WO 2003029416	A3	20040212		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,				

CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002343462	A1	20030414	AU 2002-343462	20021001
US 2003072773	A1	20030417	US 2002-262238	20021001
US 7041489	B2	20060509		
PRIORITY APPLN. INFO.:			US 2001-326259P P	20011001
			US 2002-397289P P	20020719
			WO 2002-US31086 W	20021001

AB The present invention provides recombinant respiratory syncytial viruses (RSV) in which all of the surface glycoprotein genes encoding the attachment protein G, the fusion protein F, and the Small Hydrophobic protein SH are deleted. The genes are replaced by a chimeric gene encoding a heterologous entry protein derived from the Vesicular Stomatitis Virus G protein or GP64 of baculovirus. Alternatively, the replacement proteins are provided in trans. Marker genes such as those encoding β-glucuronidase (GUS) and green fluorescent protein (EGFP) are also added to the upstream and downstream, side of hybrid gene for easy detection. These infectious recombinant respiratory syncytial viruses offer alternatives and improvements as vaccine candidates.

L11 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2001:816888 CAPLUS
DOCUMENT NUMBER:	135:353763
TITLE:	Recombinant lentiviral vectors pseudotyped in envelopes containing filovirus binding domains for gene delivery in vitro and in vivo
INVENTOR(S):	Kobinger, Gary; Wilson, James M.
PATENT ASSIGNEE(S):	The Trustees of the University of Pennsylvania, USA
SOURCE:	PCT Int. Appl., 50 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083730	A2	20011108	WO 2001-US12880	20010420
WO 2001083730	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2004033604	A1	20040219	US 2002-257960	20021025
PRIORITY APPLN. INFO.:			US 2000-200599P P	20000428
			WO 2001-US12880 W	20010420

AB The present invention provides a recombinant transfer virus, in which a lentiviral, in particular HIV, minigene is packaged in a heterologous envelope comprising the binding domain of a filovirus envelope protein. In one particularly desirable embodiment, the filovirus is ebola. Advantageously, the recombinant transfer virus of the invention minimizes the safety concerns that the HIV will form replication competent virus. The lentivirus minigene contains the lentivirus 5' long terminal repeat (LTR) sequences, a mol. for delivery to a host cell, and a functional portion of the lentivirus 3' LTR sequences. In one embodiment, the minigene further contains functional lentiviral RRE (rev-responsive element). These transfer viruses are particularly useful for delivery of mols., in vivo, to mammalian lung cells, as the transfer virus infects from the apical side, permitting delivery via intracheal administration, or for delivery of mols., ex vivo, to macrophages and dendritic cells.

Also described are methods of producing these transfer viruses in vitro, or using a packaging cell, and methods of using these viruses to deliver genes to selected target cells. In a tracheal explant model of cystic fibrosis (CF), CF explanted airway could be efficiently transduced using the EboZ pseudotyped virus of the invention despite the presence of some mucus. Thus, the transfer viruses of the invention are particularly well suited for delivery of mols. to airway cells, e.g., for treatment of CF.

=> D L4 IBIB T 1-20
'T' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):Title
'TITLE' IS NOT A VALID FORMAT
In a multifile environment, a format can only be used if it is valid
in at least one of the files. Refer to file specific help messages
or the STNGUIDE file for information on formats available in
individual files.
REENTER DISPLAY FORMAT FOR ALL FILES (FILEDEFAULT):IBIB

L4 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1009158 CAPLUS
DOCUMENT NUMBER: 145:383333
TITLE: Virus-like particles containing modified surface envelope glycoprotein and uses thereof as vaccines
INVENTOR(S): Compans, Richard W.; Yang, Chinglai; Yao, Qizhi; Kang, Sang-Moo
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 57pp., Cont.-in-part of U.S. Ser. No. 514,462.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006216702	A1	20060928	US 2006-397830	20060404
WO 2004042001	A2	20040521	WO 2003-US15930	20030519
WO 2004042001	A3	20060119		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2006088909	A1	20060427	US 2004-514462	20041112

PRIORITY APPLN. INFO.:

US 2002-381557P	P	20020517
US 2003-454115P	P	20030311
US 2003-454139P	P	20030311
US 2003-454584P	P	20030314
US 2003-468318P	P	20030506
US 2003-471246P	P	20030516
WO 2003-US15930	W	20030519
US 2004-514462	A2	20041112

L4 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:872008 CAPLUS
DOCUMENT NUMBER: 145:247073
TITLE: Generation of an adenoviral vaccine vector based on simian adenovirus 21
AUTHOR(S): Roy, Soumitra; Zhi, Yan; Kobinger, Gary P.; Figueredo, Joanita; Calcedo, Roberto; Miller, James R.; Feldmann, Heinz; Wilson, James M.
CORPORATE SOURCE: Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, 19104, USA
SOURCE: Journal of General Virology (2006), 87(9), 2477-2485
CODEN: JGVIAY; ISSN: 0022-1317
PUBLISHER: Society for General Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:736506 CAPLUS
DOCUMENT NUMBER: 145:187051
TITLE: Vaccines comprising vaccine delivery-facilitating mucosal targeting ligands (MTLs) fused to the β-trefoil domain of botulinum toxin
INVENTOR(S): Pascual, David W.; Maddaloni, Massimo
PATENT ASSIGNEE(S): Montana State University, USA
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006078567	A2	20060727	WO 2006-US1346	20060113
WO 2006078567	A3	20070215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-644991P P 20050121

L4 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:711095 CAPLUS
DOCUMENT NUMBER: 145:183885
TITLE: The signal peptide of the Ebolavirus glycoprotein influences interaction with the cellular lectins DC-SIGN and DC-SIGNR
AUTHOR(S): Marzi, Andrea; Akhavan, Armin; Simmons, Graham; Gramberg, Thomas; Hofmann, Heike; Bates, Paul; Lingappa, Vishwanath R.; Poehlmann, Stefan
CORPORATE SOURCE: Institute for Clinical and Molecular Virology, University Erlangen-Nuernberg, Erlangen, 91054, Germany

SOURCE: Journal of Virology (2006), 80(13), 6305-6317
CODEN: JOVIAM; ISSN: 0022-538X
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:117015 CAPLUS
DOCUMENT NUMBER: 144:186001
TITLE: Chimeric proteins comprising influenza virus hemagglutinin and and HIV-1 Env glycoprotein and their use in recombinant viral vaccines
INVENTOR(S): Daniels, Rodney Stuart; Copeland, Kathryn Marie; Elliot, Alexander James
PATENT ASSIGNEE(S): Medical Research Council, UK
SOURCE: PCT Int. Appl., 78 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006013367	A2	20060209	WO 2005-GB3053	20050802
WO 2006013367	A3	20060406		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	GB 2004-17390	A	20040804
	US 2004-598674P	P	20040804

L4 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:13711 CAPLUS
DOCUMENT NUMBER: 144:106605
TITLE: Hybrid peptides comprising Ii-Key peptide and antigenic epitope as vaccines against infection, allergy and cancer
INVENTOR(S): Humphreys, Robert; Xu, Minzhen
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 142 pp., Cont.-in-part of U.S. Ser. No. 245,871.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006002947	A1	20060105	US 2005-33039	20050111
US 6432409	B1	20020813	US 1999-396813	19990914
US 2003091582	A1	20030515	US 2002-197000	20020717

US 7205274	B2	20070417			
US 2003235594	A1	20031225	US 2002-245871		20020917
WO 2006076410	A2	20060720	WO 2006-US944		20060111

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	US 1999-396813	A3 19990914
	US 2002-197000	A2 20020717
	US 2002-245871	A2 20020917
	US 2005-33039	A 20050111

L4 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2005:612326 CAPLUS
DOCUMENT NUMBER:	143:131819
TITLE:	Identification of two linear epitopes on Ebola or Marburg virus glycoproteins critical for infection
INVENTOR(S):	Wilson, Carolyn A.; Mpanju, Onesmo
PATENT ASSIGNEE(S):	The Government of the United States of America, as Represented by the Secretary Department of Health and Human Services, USA
SOURCE:	PCT Int. Appl., 62 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063798	A1	20050714	WO 2004-US43360	20041223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:	US 2003-532677P	P 20031223
REFERENCE COUNT:	7	THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER:	2004:252189 CAPLUS
DOCUMENT NUMBER:	140:286142
TITLE:	Hybrid polypeptides comprising Ii-key motif and MHC class I or II-presented epitope of antigen, allergen or tumor antigen as vaccines against infection, allergy and cancer
INVENTOR(S):	Humphreys, Robert E.; Xu, Minzhen
PATENT ASSIGNEE(S):	Antigen Express, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 90 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004058881	A1	20040325	US 2002-253286	20020924
US 7179645	B2	20070220		
CA 2499123	A1	20040415	CA 2003-2499123	20030912
WO 2004030616	A2	20040415	WO 2003-US28574	20030912
WO 2004030616	A3	20041007		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003294220	A1	20040423	AU 2003-294220	20030912
EP 1556072	A2	20050727	EP 2003-789700	20030912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515744	T	20060608	JP 2004-541534	20030912
PRIORITY APPLN. INFO.:			US 2002-245871 A	20020917
			US 2002-253286 A	20020924
			WO 2003-US28574 W	20030912

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:892534 CAPLUS
DOCUMENT NUMBER: 139:386332
TITLE: Chimeric ebola virus envelopes and uses for delivering molecules to target cells
INVENTOR(S): Wilson, James M.; Medina, Maria Fe C.; Kobinger, Gary
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092582	A2	20031113	WO 2003-US11494	20030428
WO 2003092582	A3	20040701		
WO 2003092582	B1	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2003232004	A1	20031117	AU 2003-232004		20030428
US 2005255123	A1	20051117	US 2005-510947		20050111
PRIORITY APPLN. INFO.:			US 2002-376480P	P	20020430
			US 2002-385704P	P	20020604
			US 2002-427752P	P	20021120
			WO 2003-US11494	W	20030428

L4 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:282705 CAPLUS
DOCUMENT NUMBER: 138:282319
TITLE: Construction of recombinant respiratory syncytial viruses with deleted surface glycoprotein genes and uses as vaccine
INVENTOR(S): Wertz, Gail W.; Megaw, George; Oomens, Tom A.
PATENT ASSIGNEE(S): UAB Research Foundation, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003029416	A2	20030410	WO 2002-US31086	20021001
WO 2003029416	A3	20040212		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002343462	A1	20030414	AU 2002-343462	20021001
US 2003072773	A1	20030417	US 2002-262238	20021001
US 7041489	B2	20060509		
PRIORITY APPLN. INFO.:			US 2001-326259P	P 20011001
			US 2002-397289P	P 20020719
			WO 2002-US31086	W 20021001

L4 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:777969 CAPLUS
DOCUMENT NUMBER: 137:293531
TITLE: Bivalent vaccine vectors expressing chimeric filovirus glycoproteins for protection against Ebola and Marburg virus
INVENTOR(S): Grogan, Case C.; Hevey, Michael C.; Schmaljohn, Alan L.
PATENT ASSIGNEE(S): U.S. Army Medical Research Institute of Infectious Diseases, USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079239	A2	20021010	WO 2002-US3339	20020131
WO 2002079239	A9	20021212		
WO 2002079239	A3	20031002		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002303086	A1	20021015	AU 2002-303086	20020131
US 2003108560	A1	20030612	US 2002-66506	20020131
PRIORITY APPLN. INFO.:			US 2001-267522P	P 20010131
			WO 2002-US3339	W 20020131

L4 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:634334 CAPLUS
DOCUMENT NUMBER: 137:180775
TITLE: Influenza viruses with enhanced transcription and replication capacities comprising RNA polymerase similar to that of fowl plague virus and uses for gene therapy and vaccination
INVENTOR(S): Hobom, Gerd; Menke, Anette
PATENT ASSIGNEE(S): Artemis Pharmaceuticals Gmbh, Germany
SOURCE: Eur. Pat. Appl., 137 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1233059	A1	20020821	EP 2001-103060	20010209
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
WO 2002064757	A2	20020822	WO 2002-EP1257	20020207
WO 2002064757	A3	20021205		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002247689	A1	20020828	AU 2002-247689	20020207
EP 1368459	A2	20031210	EP 2002-716735	20020207
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004531232	T	20041014	JP 2002-565072	20020207
US 2003099670	A1	20030529	US 2002-73377	20020208
PRIORITY APPLN. INFO.:			EP 2001-103060	A 20010209
			US 2001-270135P	P 20010220
			WO 2002-EP1257	W 20020207

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:885623 CAPLUS
DOCUMENT NUMBER: 136:36320
TITLE: Genetic vaccines that mimic natural viral infection
INVENTOR(S): Wang, Danher
PATENT ASSIGNEE(S): Genphar, Inc., USA

SOURCE: PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001091536	A2	20011206	WO 2001-US18238	20010604
WO 2001091536	A3	20020808		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6544780	B1	20030408	US 2000-585599	20000602
CA 2410543	A1	20011206	CA 2001-2410543	20010604
AU 200171288	A	20011211	AU 2001-71288	20010604
EP 1286694	A2	20030305	EP 2001-950275	20010604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003534016	T	20031118	JP 2001-587560	20010604
US 2002155127	A1	20021024	US 2001-3035	20011101
US 2003219458	A1	20031127	US 2002-280915	20021024
US 2004265336	A9	20041230		
US 2003138459	A1	20030724	US 2002-286332	20021101
US 2004185064	A9	20040923		
ZA 2002009676	A	20031128	ZA 2002-9676	20021128
US 2004028652	A1	20040212	US 2002-327294	20021219
US 6964762	B2	20051115		

PRIORITY APPLN. INFO.:		
US 2000-585599	A	20000602
WO 2001-US18238	W	20010604
US 2001-3035	A1	20011101

L4 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2001:816888 CAPLUS
DOCUMENT NUMBER: 135:353763
TITLE: Recombinant lentiviral vectors pseudotyped in envelopes containing filovirus binding domains for gene delivery in vitro and in vivo
INVENTOR(S): Kobinger, Gary; Wilson, James M.
PATENT ASSIGNEE(S): The Trustees of the University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083730	A2	20011108	WO 2001-US12880	20010420
WO 2001083730	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2004033604	A1	20040219	US 2002-257960		20021025
PRIORITY APPLN. INFO.:			US 2000-200599P	P	20000428
			WO 2001-US12880	W	20010420

L4 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:855389 CAPLUS
DOCUMENT NUMBER: 134:160015
TITLE: Downregulation of β1 Integrins by Ebola Virus Glycoprotein: Implication for Virus Entry
AUTHOR(S): Takada, Ayato; Watanabe, Shinji; Ito, Hiroshi; Okazaki, Katsunori; Kida, Hiroshi; Kawaoka, Yoshihiro
CORPORATE SOURCE: Laboratory of Microbiology, Department of Disease Control, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan
SOURCE: Virology (2000), 278(1), 20-26
CODEN: VIRLAX; ISSN: 0042-6822
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:336300 CAPLUS
DOCUMENT NUMBER: 129:91929
TITLE: The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is along triple-stranded coiled coil
AUTHOR(S): Weissenhorn, Winfried; Calder, Lesley J.; Wharton, Stephen A.; Skehel, John J.; Wiley, Don C.
CORPORATE SOURCE: Lab. Molecular Med., Howard Hughes Medical Inst., The Children's Hosp., Boston, MA, 02215, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1998), 95(11), 6032-6036
CODEN: PNASA6; ISSN: 0027-8424
PUBLISHER: National Academy of Sciences
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:631626 CAPLUS
DOCUMENT NUMBER: 127:225278
TITLE: Genetic vectors delivery to target cells by complexation with non-viral carrier compositions and use for expressing genes in cells and gene therapy
INVENTOR(S): Sedlacek, Hans Harald; Klenk, Hans-Dieter; Kissel, Thomas; Mueller, Rolf
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Ger. Offen., 20 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

DE 19605279	A1	19970814	DE 1996-19605279	19960213
EP 790312	A2	19970820	EP 1997-101506	19970131
EP 790312	A3	19990901		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CA 2197265	A1	19970814	CA 1997-2197265	19970211
AU 9712651	A	19970821	AU 1997-12651	19970211
AU 716916	B2	20000309		
ZA 9701159	A	19971113	ZA 1997-1159	19970212
HU 9700428	A2	19980629	HU 1997-428	19970212
JP 10004979	A	19980113	JP 1997-29462	19970213
US 5916803	A	19990629	US 1997-799825	19970213
US 6358524	B1	20020319	US 1999-280068	19990329
PRIORITY APPLN. INFO.:			DE 1996-19605279	A 19960213
			US 1997-799825	A1 19970213

L4 ANSWER 18 OF 20 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2006:597337 BIOSIS
DOCUMENT NUMBER: PREV200600591272
TITLE: Generation of an adenoviral vaccine vector based on simian adenovirus 21.
AUTHOR(S): Roy, Soumitra; Zhi, Yan; *Kobinger, Gary P.; Figueredo, Joanita; Calcedo, Roberto; Miller, James R.; Feldmann, Heinz; Wilson, James M. [Reprint Author]
CORPORATE SOURCE: Univ Penn, Sch Med, Gene Therapy Program, Dept Pathol and Lab Med, Philadelphia, PA 19104 USA
wilsonjm@mail.med.upenn.edu
SOURCE: Journal of General Virology, (SEP 2006) Vol. 87, No. Part 9, pp. 2477-2485.
CODEN: JGVIAY. ISSN: 0022-1317.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 8 Nov 2006
Last Updated on STN: 8 Nov 2006

L4 ANSWER 19 OF 20 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 2001:84119 BIOSIS
DOCUMENT NUMBER: PREV200100084119
TITLE: Downregulation of beta1 integrins by Ebola virus glycoprotein: Implication for virus entry.
AUTHOR(S): Takada, Ayato; Watanabe, Shinji; Ito, Hiroshi; Okazaki, Katsunori; Kida, Hiroshi; Kawaoka, Yoshihiro [Reprint author]
CORPORATE SOURCE: Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive West, Madison, WI, 53706, USA
kawaokay@svm.vetmed.wisc.edu
SOURCE: Virology, (December 5, 2000) Vol. 278, No. 1, pp. 20-26. print.
CODEN: VIRLAX. ISSN: 0042-6822.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L4 ANSWER 20 OF 20 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN

ACCESSION NUMBER: 1998:312764 BIOSIS
DOCUMENT NUMBER: PREV199800312764
TITLE: The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil.
AUTHOR(S): Weissenhorn, Winfried; Calder, Lesley J.; Wharton, Stephen

A.; Skehel, John J.; Wiley, Don C. [Reprint author]

CORPORATE SOURCE: Dep. Mol. Cell. Biol., Harv. Univ., 7 Divinity Ave., Cambridge, MA 02138-2092, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America, (May 26, 1998) Vol. 95, No. 11, pp. 6032-6036. print.
CODEN: PNASA6. ISSN: 0027-8424.

DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Jul 1998
Last Updated on STN: 15 Jul 1998

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	92.68	93.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.58	-8.58

FILE 'STNGUIDE' ENTERED AT 15:33:29 ON 23 JUL 2007

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Jul 20, 2007 (20070720/UP).

L10 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1994:1939 CAPLUS
DOCUMENT NUMBER: 120:1939
TITLE: Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus
AUTHOR(S): Sanchez, Anthony; Kiley, Michael P.; Holloway, Brian P.; Auperin, David D.
CORPORATE SOURCE: Div. viral, Natl. Cent. Infect. Dis., Atlanta, GA, 30333, USA
SOURCE: Virus Research (1993), 29(3), 215-40
CODEN: VIREDF; ISSN: 0168-1702
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Sequence anal. of the 2nd through the 6th genes of the Ebola virus (EBO) genome indicates that it is organized similarly to rhabdoviruses and paramyxoviruses and is virtually the same as Marburg virus (MBG). In vitro translation expts. and predicted amino acid sequence comparisons showed that the order of the EBO genes is 3'-NP-VP35-VP40-GP-VP30-VP24-L. The transcriptional start and stop (polyadenylation) signals are conserved and all contain the sequence 3'-UAAUU. Three base intergenic sequences are present between the NP and VP35 genes (3'-GAU) and VP40 and GP genes (3'-AGC), and a large intergenic sequence of 142 bases separates the VP30 and VP24 genes. Novel gene overlaps were found between the VP35 and VP40, the GP and VP30, and the VP24 and L genes. Overlaps are 20 or 18 bases in length and are limited to the conserved sequences determined for the transcriptional signals. Stem-and-loop structures were identified in the putative (+) leader RNA and at the 5' end of each mRNA. Hybridization studies showed that a small 2nd mRNA is transcribed from the glycoprotein gene, and is produced by termination of transcription at an atypical polyadenylation signal located in the middle of the coding region. The predicted amino acid sequence of the glycoprotein contains an N-terminal signal peptide sequence, a hydrophobic anchor sequence, and 17 potential N-linked glycosylation sites. Alignment of predicted amino acid sequences showed that the structural proteins of EBO and MBG contain large regions of homol. despite the absence of serol. cross-reactivity.

L10 ANSWER 7 OF 7 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on S